MPV has been reported as a useful biomarker in early identification of patients with stable coronary artery disease at high risk of post-PCI low-reflow. Studies have shown that pre-procedural elevated MPV is associated with the incidence of major adverse cardiac event and restenosis following PCI. 16 The study submitted that MPV is a potential marker of restenosis after PCI. Another study reported that MPV independently predicted post-PCI-corrected thrombolysis in myocardial infarction frame count. 17 Similar to the effects of MPV on AMI, several studies have found that an elevated MPV is a strong independent predictor of long-term outcomes after PCI. 4,18 However, one study found that mortality increased when the MPV rose overtime after PCI, but the pre-procedural MPV was not predictive in this context. 19 It was suggested that monitoring MPV after PCI might aid in risk classification.
Mean platelet volume and residual platelet interference in dual antiplatelet therapy
Antiplatelet therapy reduces the incidence of both procedure-related complications and ischemic cardiovascular events after PCI. 20 Particularly, dual antiplatelet therapy (aspirin and an ADP receptor inhibitor) is the present standard of care after implantation of drug-eluting stents. Nevertheless, high residual platelet reactivity can limit the utility of antiplatelet therapy, increasing the frequency of cardiovascular events both during the procedure and during long-term follow-up. 21, 22 However, Paulu et al., 23 in a prospective observational study, showed that clopidogrel resistance was not of prognostic utility in an unselected cohort of 378 patients who underwent PCI. In addition, Collet et al., 24 observed no significant improvement in clinical outcomes when platelet function was monitored and adjusted in patients who underwent coronary stenting, compared to those who received standard atiplatelet therapy (without monitoring); this was a large, randomized open-label study on 2,440 patients.
Platelet activity testing can be time-consuming, expensive, and technically complex. 25 However, MPV can be readily measured before PCI using automated hematology analyzers. Recently, Kim et al., 26 suggested that a high MPV was associated with reduced responses to aspirin and clopidogrel. Some investigators have suggested that an increase in MPV overtime after PCI is associated with high ontreatment platelet reactivity. 5 Moreover, Choi et al. 4 suggested that MPV was superior to platelet function testing in terms of predicting cardiac death or cardiovascular events in patients who had undergone PCI, particularly those in an acute coronary syndrome subgroup.
Limitations
MPV can be simply and inexpensively determined and does not require professional interpretation. However, there are several limitations to using MPV as an indicator of heart disease. This is because most relevant studies have been retrospective in nature, enrolled small numbers of patients, or had confounding factors that may have affected platelet volume. 27 Furthermore, a wide range of cut-off values has been used in retrospective studies, emphasizing that prospective works are needed.
Conclusions
Many studies have shown associations between an elevated MPV and poor clinical outcomes after PCI in patients with coronary artery disease. The marker also affords valuable insights into how to identify patients at high risk for coronary artery disease after PCI, and provides useful guidance as to when additional adjunctive therapy is needed to improve clinical outcomes. 
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